Loading
companiesCompany
Sutro Biopharma
Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.
Overview
STRO-004 (tissue factor, DAR8 TOP1 payload) is the lead, with first clinical data expected mid-2026; STRO-227 is a DAR10 dual-payload PTK7 ADC (MMAE DAR2 + TOP1 DAR8) with IND planned 2026. Luveltamab tazevibulin (FRα) development stopped pending a partner. Site-specific conjugation via non-natural amino acids (XpressCF).
Headquarters
South San Francisco, CA, US
Scorecard
All companies#384of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Biotech · STRO
Stage
Public
Website
Phase 3ADC
A folate-receptor ADC designed to work across low and high receptor levels, in a pivotal ovarian cancer trial.
Similar pages
- IdeaDual-payload ADCs in first line to prevent resistance
Shares Dual-payload ADC, Site-specific conjugation & linker chemistry, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
- PersonIgnace Vergote
Shares Tissue factor, Antibody-drug conjugate (ADC), Ovarian cancer.
- CompanyProfoundBio
Shares Folate receptor alpha, Antibody-drug conjugate (ADC), Ovarian cancer.
- TrialRAINFOL-01 (Rina-S)
Shares Folate receptor alpha, Antibody-drug conjugate (ADC), Ovarian cancer.
- IdeaSequence folate-receptor ADCs by payload class
Shares Luveltamab tazevibulin, Folate receptor alpha, Ovarian cancer.
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialMIRASOL / GOG-3045
Shares Folate receptor alpha, Antibody-drug conjugate (ADC), Ovarian cancer.
- PersonBradley J. Monk
Shares Tissue factor, Antibody-drug conjugate (ADC), Ovarian cancer.
cancers
fronts
technologies
targets
drugs
Phase 3ADC